Why do patients with liver metastases respond so poorly to cancer immunotherapy?
Here we find a new immunological mechanism in MMR-d cancers centering on IL-18 and γδ T cells.👇 www.cell.com/cell-reports... @cp-cellrepmed.bsky.social
cell.com
Liver metastases dampen IL18-driven γδ T cell activity and immunotherapy responsiveness in colorectal cancer
van Renterghem et al. investigate the impact of liver metastases on immunity in MMR-d/MSI-hi
patients treated with ICB. They show that IL18 activates liver-derived Vδ1+ T cells
and predicts ICB benefi...